Business Context and Reporting Period
This Form 8-K was filed by Akebia Therapeutics, Inc. on April 8, 2019, reporting material definitive agreements entered into on April 8 and April 9, 2019. Akebia is a biopharmaceutical company developing vadadustat, an investigational oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease (CKD).
Key Financial Metrics and Agreements
The filing details two primary commercial agreements rather than standard financial performance metrics:
- Amended and Restated License Agreement with Vifor (International) Ltd.: Akebia granted Vifor an exclusive license to sell vadadustat to Fresenius Kidney Care Group LLC and approved third-party dialysis organizations in the U.S.
- Milestone Payment: Vifor is obligated to pay a $25 million milestone upon the occurrence of FDA approval for dialysis-dependent CKD patients and a determination by CMS regarding reimbursement (either inclusion in the bundled model or TDAPA).
- Profit Share Structure: The agreement is structured as a profit share where Akebia receives a majority of profits from Vifor's sales after cost deductions. Akebia will share this milestone and revenue with Otsuka Pharmaceutical Co. Ltd.
- Commercial Supply Agreement with Esteve Química, S.A.: A four-year agreement (April 9, 2019 to April 9, 2023) for the manufacture of vadadustat drug substance (API) with a volume-based pricing structure.
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes Versus Prior Period
The primary material change is the amendment of the May 12, 2017 License Agreement with Vifor. The new agreement clarifies the scope of the license to include specific dialysis organizations and establishes the conditions for the $25 million milestone payment. Additionally, the company secured a new four-year supply agreement with Esteve for commercial API production, which was not present in the prior period.
Guidance, Outlook, Risks, and Contingencies
Outlook and Contingencies:
- The $25 million milestone is contingent upon FDA approval and specific CMS reimbursement determinations.
- Akebia retains rights to commercialize vadadustat for non-dialysis dependent CKD markets and other dialysis organizations in collaboration with Otsuka.
- Vifor may terminate the agreement with 12 months' notice after the release of first topline Phase 3 data.
Risks:
- Failure to achieve the milestone or expected profits.
- Potential termination of agreements by either party.
- Uncertainty regarding FDA approval and CMS reimbursement models (bundled vs. TDAPA).
- Capital constraints affecting clinical program enrollment and completion.
- Competitive landscape and intellectual property enforcement.
Key Facts for Investor Verification
- Verify the specific conditions required for the $25 million milestone payment (FDA approval and CMS reimbursement status).
- Confirm the profit-sharing split between Akebia, Vifor, and Otsuka under the amended agreement.
- Monitor the status of the vadadustat global Phase 3 program for dialysis-dependent CKD patients, as this triggers Vifor's termination rights.
- Review the volume-based pricing terms in the supply agreement with Esteve to assess future cost of goods sold.
- Check for updates on CMS decisions regarding vadadustat's inclusion in the bundled reimbursement model or TDAPA.